Opioids

Glowing puzzle piece fitting into puzzle

Biotech

Eolas regains opioid use disorder drug abandoned by AstraZeneca

AZ ended work on the orexin 1 receptor antagonist in November after a phase 2 study identified a “potential drug-drug interaction" with itraconazole.

James Waldron Jul 10, 2025 9:33am

pain addiction pills suffering

Tris' next-gen pain drug completes trio of clinical wins

Mar 6, 2025 8:30am

power lines at dusk

Novo Holdings-backed SiteOne charges up with $100M financing

Dec 18, 2024 7:00am

AstraZeneca cans ph. 2 OUD drug over antifungal interaction

Nov 22, 2024 4:41am

unstable stay back warning

With 4 remaining staffers, CNS-focused Trevena nears end of road

Nov 7, 2024 10:40am

Hydrocodone pills spill out of a bottle

FDA approves first DNA test for opioid use disorder risks

Dec 21, 2023 10:18am